Cells in the body have specific purposes, but stem cells are cells that do not yet have a specific role and can become almost any cell that is required.Stem cells are undifferentiated cells that can turn into specific cells, as the body needs them.
Scientists and doctors are interested in stem cells as they help to explain how some functions of the body work, and how they sometimes go wrong.Stem cells also show promise for treating some diseases that currently have no cure.
Stem cells originate from two main sources: adult body tissues and embryos. Scientists are also working on ways to develop stem cells from other cells, using genetic “reprogramming” techniques.
Stem cell therapy, also known as regenerative medicine, promotes the repair response of diseased, dysfunctional,orinjured tissue using stem cells or their derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply.
In stem cell transplants, stem cells replace cells damaged by chemotherapy or disease or serve as a way for the donor’s immune system to fight some types of cancer and blood-related diseases, such as leukemia, lymphoma, neuroblastoma and multiple myeloma. These transplants use adult stem cells or umbilical cord blood.
With the continuous change/development in the healthcare system, most cases like Leukaemia can be treated with Chemotherapy or Stem cell Transplantation.
Our Focus is on the stem cell transplantation treatment which the Spetra Optia Apheresis Machine excels at.
A stem cell transplant can be used to restore healthy bone marrow in patients with leukemia. Stem cells help stimulate new bone marrow growth and restore the immune system.
The two main types of stem cell transplants are:
In this procedure, stem cells are collected from the patient’s blood, harvested, frozen and stored until needed, then infused back into the patient after he/she has received high dose chemotherapy and/or radiation therapy to destroy the cancer cells.
In this type of transplant, stem cells are taken from a matching donor. To determine if a donor’s stem cells are the right match, the patient undergoes a human leukocyte antigens (HLA) test. In an HLA test, we compare the patient’s blood and tissue type with blood samples from the donor.
Before a stem cell transplant for leukemia, you will undergo a conditioning regimen.
Once this preparative regimen is complete, you are ready to undergo the transplant. Much like a blood transfusion, you’ll receive the stem cells intravenously. After entering the bloodstream, the stem cells travel to the bone marrow and start to make new blood cells in a process known as engraftment.
In the months following the transplant, your care team will monitor your blood counts. You may need transfusions of red blood cells and platelets. Sometimes, the intensive treatments you receive before the stem cell transplantation for leukemia can cause side effects, such as infection. In this case, your doctor may administer IV antibiotics.
An advantage of an allogeneic transplant is that the stem cells come from a healthy donor with no malignant cells. However, since it can be difficult to find a matching donor, an autologous transplant is usually more common. Also, if you had an allogeneic stem cell transplant, your doctor may prescribe certain drugs to reduce the risk of graft-versus-host-disease (GVHD), a condition where the donated cells attack the patient’s tissues.
Recovery from a leukemia stem cell transplant may take several months. Your hematologic oncology team will work together with the rest of your care team to support you throughout the process.
A dependable Brand like Terumo using the Spectra Optia Apheresis machine can carry out Stem cell Apheresis procedure using the continuous mononuclear cell collection protocol. This Spectra Optia Apheresis Machine is available for purchase from Sudabelt Medical.
Background: The aim of the study was to assess the performance of the new Continuous Mononuclear Cell Collection (CMNC) protocol on the Spectra Optia Apheresis Machine System for collecting autologous Peripheral Blood Stem Cells (PBSC) in adult patients with respect to collection variables, CD34+ cells harvest prediction and engraftment data. In this retrospective study, 39 CMNC procedures on 23 mobilized patients with multiple myeloma and lymphoma were analyzed. CD34+ cells and blood cells yields, collection efficiencies (CE1 and CE2), cell losses were calculated. Engraftment data of 17 autologous transplantations were collected.
Results: Apheresis duration was 239 min for a product volume of 220 mL. Cell product haematocrit, MNC and platelets counts were acceptable (respectively 2.4%, 65%, 834 x 109/L). Median platelet loss was 27.3%. Median CD34+ CE1 and CE2 were 64.6% and 48.5% respectively. We harvested 2.92 × 106 CD34+ cells/kg, with a CD34 dose ≥ 2 × 106 /kg for 67% of the procedures. Linear correlation between preapheresis CD34 count and the CP CD34 dose/kg allowed a prediction model with a decrease trend for high WBC precount. Procedures were well tolerated. For 17 autologous transplantations, median time to neutrophils and platelets reconstitutions were 12 and 13 days respectively.
Conclusions: Spectra Optia CMNC protocol successfully collected CD34+ cells with yields permitting the harvest of sufficient enriched grafts for autologous transplantation. The CD34+ cell yield prediction was excellent. PBSC collection with CMNC protocol had advantages of high processing rate, low product volume, and acceptable contamination by platelets.